| (Values in U.S. Thousands) | Mar, 2026 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 |
| Sales | 34,938 | 30,903 | 47,687 | 29,409 | 48,330 |
| Sales Growth | +13.06% | -35.20% | +62.15% | -39.15% | -1.83% |
| Net Income | -31,203 | -32,073 | -50,019 | -44,355 | -11,586 |
| Net Income Growth | +2.71% | +35.88% | -12.77% | -282.83% | -25.50% |
Valneva Se (VLA.FP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Fiscal Year End Date: 12/31